PRO 140
PRO 140
PRO 140 (pronounced P-R-O One-Four-Zero) is a monoclonal antibody designed to treat HIV and AIDS. It is a biological therapy that works by blocking the CCR5 receptor, which the HIV virus uses to enter and infect T cells.
Etymology
The name "PRO 140" is derived from its development by the biotechnology company Progenics Pharmaceuticals. The "140" does not have a known specific meaning.
Mechanism of Action
PRO 140 works by binding to the CCR5 receptor on the surface of T cells. This prevents the HIV virus from attaching to the cell and entering it, thereby preventing the virus from replicating and spreading throughout the body.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- CCR5: A protein on the surface of white blood cells that is involved in the immune system as it functions as a receptor for chemokines.
- HIV: Human Immunodeficiency Virus, the virus that causes AIDS.
- AIDS: Acquired Immunodeficiency Syndrome, a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV).
- T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity, the system that tailors the body's immune response to specific pathogens.
External links
- Medical encyclopedia article on PRO 140
- Wikipedia's article - PRO 140
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski